A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Thalomid
Synonyms :
thalidomide
Class :
Antineoplastics, Angiogenesis Inhibitors
Brand Name :
Thalomid
Synonyms :
thalidomide
Class :
Antineoplastics, Angiogenesis Inhibitors
Dosage Forms & StrengthsÂ
Capsule Â
50 mg Â
100 mg Â
150 mg Â
200 mg Â
Take a dose of 200 mg orally one time a day at bedtime minimum one hour after the evening food
Total duration of therapy is 28-days treatment cycles
Dosing Considerations
During the four weeks prior to starting therapy, during therapy, during dose interruptions, and for the four weeks following therapy completion, females those who are pregnant must abstain from pregnancy
Dosage Forms & StrengthsÂ
CapsuleÂ
50 mgÂ
100 mgÂ
150 mgÂ
200 mgÂ
For <12 years: Safety and efficacy not determined
For ≥12 years old:
Take an initial dose of 100 to 300 mg orally every day at bedtime minimum one hour after evening food
Refer to adult dosingÂ
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
An increase in the chances of the formation of fatal blood clots is seen when thalidomide and peginesatide are administered together
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the effect of CNS depression of thalidomide
CNS depressants increase the effect of CNS depression of thalidomide
CNS depressants increase the effect of CNS depression of thalidomide
may have an increased CNS depressive effect when combined with thalidomide
may have an increased CNS depressive effect when combined with thalidomide
may have an increased CNS depressive effect when combined with thalidomide
CNS depressants increase the efficacy of thalidomide
CNS depressants increase the efficacy of thalidomide
CNS depressants increase the efficacy of thalidomide
It may increase the CNS depressant effect when combined with CNS Depressants
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of peripheral neuropathy   
when both drugs are combined, there may be an increased risk or severity of peripheral neuropathy  
when both the drugs are combined, the risk or severity of adverse effects decreases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk of dangerous blood clots  
when both drugs are combined, there may be an increased risk of dangerous blood clots  
taken in combination; with thalidomide and nivolumab for treating multiple myeloma may result in serious risk and life-threatening effects
when both drugs are combined, there may be an increased risk of severe and life-threatening side effects as well as death  
CNS depressants increase the effect of thalidomide
CNS depressants increase the effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
CNS depressants increase the CNS suppression effect of thalidomide
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of certolizumab pegol
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effects of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
respiratory syncytial virus vaccine, adjuvanted
may diminish the pharmacodynamic antagonistic effect of each other when combined
respiratory syncytial virus (RSV) vaccine
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
CNS Depressants may enhance the CNS depressant effect of thalidomide
CNS Depressants may enhance the CNS depressant effect of thalidomide
CNS Depressants may enhance the CNS depressant effect of thalidomide
CNS Depressants may enhance the CNS depressant effect of thalidomide
CNS Depressants may enhance the CNS depressant effect of thalidomide
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
may have an increased thrombogenic effect when combined with thalidomide
thalidomide: they may increase the thrombogenic effect of hormonal contraceptives
thalidomide: they may increase the thrombogenic effect of hormonal contraceptives
thalidomide: they may increase the thrombogenic effect of hormonal contraceptives
thalidomide: they may increase the thrombogenic effect of hormonal contraceptives
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
It may enhance the risk of adverse effects when combined with Antipsoriatics drugs
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
methoxypolyethylene glycol-epoetin betaÂ
methoxy polyethylene glycol-epoetin beta in combination with thalidomide may enhance the risk or severity of thrombosis
hormonal contraceptives increase the effect of thrombogenesis of thalidomide
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
may increase the thrombogenic effect of Erythropoiesis-Stimulating Agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
the risk of adverse effects can be increased
Actions and SpectrumÂ
thalidomide has immunomodulatory properties. It can affect the immune system by reducing inflammation and inhibiting the production of certain cytokines, such as tumor necrosis factor-alpha (TNF-α). Â
thalidomide and its derivatives have been used in the treatment of various inflammatory and autoimmune conditions, including leprosy, multiple myeloma, and certain skin conditions. Â
Frequency defined Â
>10% (MM All Grades)Â
Tremor Â
Fever Â
Constipation Â
Neuropathy-sensory Â
Dyspnea Â
Fatigue Â
Hypocalcemia Â
Edema Â
Muscle weakness Â
Neutrophils decreased Â
Rash/desquamation Â
Confusion Â
Leukocytes decreased Â
Peripheral edema Â
Anorexia Â
Nausea Â
>10% (ENL)Â
Somnolence Â
Rash Â
Leukopenia Â
FeverÂ
Asthenia Â
Headache Â
DiarrheaÂ
Dizziness Â
Maculopapular rash Â
Paresthesia Â
Sweating Â
Post marketing ReportsÂ
Sick sinus syndromeÂ
Pulmonary hypertensionÂ
Digestive systemÂ
Intestinal perforationÂ
Gastrointestinal perforationsÂ
Bile duct obstructionÂ
Stomach ulcerÂ
AphthousÂ
StomatitisÂ
Erythema multiforme Â
Erythema nodosumÂ
Toxic epidermal necrolysis (TEN)Â
PurpuraÂ
PetechiaeÂ
Hypersensitivity including anaphylaxisÂ
Black Box WarningÂ
Thalidomide can cause severe, life-threatening birth defects or death to an unborn child. For females, thalidomide is only available under a special program called THALOMID REMS. Â
Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking thalidomide and for up to 28 days after discontinuing thalidomide, even if they have undergone a successful vasectomy.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
thalidomide has immunomodulatory effects by changing the activity of the immune system. It is thought to work in part by inhibiting the production of various pro-inflammatory cytokines, with a strong effect on tumor necrosis factor-alpha (TNF-α). Â
PharmacodynamicsÂ
thalidomide’s anti-angiogenic effects involve the inhibition of angiogenesis, the formation of new blood vessels. This is completely by reducing the production of pro-angiogenic factors. Â
PharmacokineticsÂ
Absorption  Â
thalidomide is absorbed from the gastrointestinal tract into the bloodstream.Â
DistributionÂ
thalidomide is widely distributed throughout the body.Â
MetabolismÂ
thalidomide is metabolized in the liver. Â
Elimination and excretionÂ
thalidomide is excreted in the urine.Â
AdministrationÂ
thalidomide is taken orally in the form of capsule.Â
Patient information leafletÂ
Generic Name: thalidomideÂ
Why do we use thalidomide?Â
thalidomide is used to manage erythema nodosum leprosum (ENL). Â
thalidomide is used in the treatment of multiple myeloma.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
